Observed Signal · Sep 24, 2026 · Clinical Data Presentation · Source: PR Newswire: Advertising & Marketing · Impact: 1/5 · Sentiment: Neutral

REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy

Executive Signal Summary

REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Clinical trial results for a gene therapy are specific to the biotech industry and not directly relevant to AdTech, MarTech, or digital advertising. While it may have indirect implications for healthcare advertising, it does not impact the advertising technology ecosystem directly.

MARKET SIGNALS

Track AbbVie Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • 60% of Dose Level 3 participants (n=6/10) achieved >2-step DRSS improvement at 3 years post-treatment.
  • No vision-threatening events or additional treatment for diabetic retinopathy observed in these participants.
  • No intraocular inflammation (IOI) observed with short-course prophylactic topical steroids through three years.
  • Data presented at Retina Society 59th Annual Scientific Meeting in Los Angeles.
  • Sura-vec is being evaluated in the Phase IIb/III NAAVIGATE trial for NPDR.

Connected Companies & Entities

“surabgene lomparvovec for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie.”

Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: PR Newswire: Advertising & Marketing•Published: Sep 24, 2026
Original Coverage Title: “REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Product & Platform LaunchSep 11, 2026

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson announced new overall survival data and treatment experience improvements for RYBREVANT-based regimens in EGFR-mutated lung cancer at WCLC 2026. Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC will be featured in a Presidential Symposium. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO and prophylactic strategies.

Read assessment
Biotech / AI Drug DiscoverySep 10, 2026

Insilico Doses First Patient in World's First Generative AI-Driven Phase III Trial

Insilico Medicine announced it has dosed the first patient in GENESIS-IPF-3, the world's first Phase III clinical trial of a generative AI-driven innovative drug. The trial evaluates Rentosertib (ISM001-055) for idiopathic pulmonary fibrosis (IPF) at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital. Rentosertib targets TNIK, a novel AI-discovered target, and showed promising Phase IIa results. The Phase III study is a 52-week, randomized, double-blind, placebo-controlled trial across 47 centers in China, enrolling 320 patients. Insilico also reported strong financial performance, with $106M revenue in H1 2026 and over $7.3B in new contract value, highlighting its AI-driven drug discovery platform's commercial viability.

Read assessment
BiotechOct 23, 2026

Intensity Therapeutics Presents INVINCIBLE-4 TNBC Data

Intensity Therapeutics announced that data from the first seven patients in Cohort A of the INVINCIBLE-4 study will be presented at the ESMO 2026 congress. The study evaluates INT230-6, an intratumoral therapy, in combination with neoadjuvant immunochemotherapy (NAIC) for early-stage triple-negative breast cancer (TNBC). Results showed a pathological complete response (pCR) in the breast and lymph nodes in 5 of 7 patients (71%). No invasive cancer cells in axillary lymph nodes were detected in 6 of 7 patients, despite 71% being initially node-positive. Tumor necrosis was observed in all patients after 1-2 injections. Adverse events were low grade, with dose-limiting skin reactions. The data suggest potential efficacy of INT230-6 in this setting.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for AbbVie & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context